Life Sciences firms, and the R&D organizations within them, are at a crossroads in terms of moving to a patient outcome oriented model. Accenture surveyed 76 R&D leaders at US and European pharmaceutical and biotechnology firms to identify what R&D teams are doing to make the fundamental shift from a product focus to a patient outcome focus—and how they are investing to ensure success.
R&D executives clearly see improving patient outcomes as a key strategy, and see a significant role for digital in their organizations to accomplish this goal. However, they are not aligned in their prioritization of these efforts. While some companies are taking a broader perspective and investing in improving internal and external collaboration—frequently by leveraging digital enablers—others remain committed to more traditional approaches.
Some of the key findings from our research include:
Improving patient outcomes ranked as the number one priority
Digital is a primary driver to become more focused on patient outcomes
Adoption of digital is inconsistent among R&D executives; half of respondents are “all in” while others are exploring or waiting
Executives report stronger performance as a result of digital adoption
Together these findings suggest that Life Sciences companies, and the R&D organizations within them, are at a crossroads in terms of moving to a patient outcome oriented model. To learn more, download: Industry at a crossroads: The rise of digital in the outcome-driven R&D organization